Navigation Links
Tablet is better all round for cancer patients
Date:10/8/2007

A drug to treat colon cancer is proving much more convenient than traditional chemotherapy, has fewer side effects - and a study of almost 2,000 patients has shown it is giving them a better chance of surviving the disease.

Standard chemotherapy can be incredibly disruptive to peoples lives, said Prof Professor Chris Twelves of the University of Leeds, who led the research. Patients visit hospital five days a week for the injections and then have three weeks off before returning to hospital for the next course and the side effects can be unpleasant.

The oral chemotherapy drug Xeloda (capecitabine) offers fewer side-effects and less time in hospital and the trial has shown that patients given the drug were at least as likely to be alive and free of their disease as those on standard chemotherapy (the Mayo Clinic regimen).

The research showed that about 71 percent of patients given Xeloda were still alive after five years, compared to 68 percent of patients treated with standard chemotherapy injections.

Prof Twelvess study followed 1,987 patients who had undergone colon cancer surgery. It found that patients treated with Xeloda spent 85 percent less time with their doctor or at the hospital, and experienced fewer side effects. The new results, showing patients five-year survival rates, confirm the effectiveness of the treatment.

We now have long-term evidence now that clearly supports Xeloda's superiority over the Mayo Clinic regimen, said Prof Twelves. There is now no reason why we should ask colon cancer patients to endure the burdens associated with that older treatment.


'/>"/>
Contact: Simon Jenkins
J.Hicks@leeds.ac.uk
0044-011-334-34031
University of Leeds
Source:Eurekalert

Page: 1

Related medicine news :

1. Clarithromycin tablets to be launched in India soon
2. Cadila gets US FDA approval for Promethazine tablets
3. Say no to detox tablets
4. Manic Ecstasy: Man gets Into a Frenzy after a Record Consumption of 40,000 ecstasy tablets
5. Three Arrested For Illegal Export Of Ephedrine Tablets
6. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
7. Cadila Gets Tentative USFDA Nod For Pravastatin Sodium Tablets
8. Lupin Gets USFDA Approval For Quinapril Tablets
9. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
10. Aurobindo Gets USFDA Approval for Didanosine Chewable Tablets
11. Ranbaxy Launches Clarithromycin, Terbinafine Tablets in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , ... December 06, 2016 , ... TopConsumerReviews.com recently gave ... Mobility Scooters . , Mobility Scooters give freedom to people who need help getting ... others may be facing a long period of rehabilitation after an illness or accident. ...
(Date:12/5/2016)... ... 2016 , ... What: Shriners Hospitals for Children, with the help of Dimension ... using a video monitor and web-enabled camera. Santa visits with children through Dimension Data’s ... Christmas Wonderland, which is where the video connection to the North Pole will stream. ...
(Date:12/5/2016)... (PRWEB) , ... December 06, 2016 , ... For many ... Lithuanian poetry , both thick and thin. The beauty of the Lithuanian language ... Trafford Publishing). , In this poetry book, Zubinas lyrically explores all aspects of a ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... leading global lifestyle design firm kathy ireland® Worldwide for five additional years, announced ... entered into an exclusive licensing agreement three years ago to design and develop ...
(Date:12/5/2016)... (PRWEB) , ... December 05, ... ... strategic interoperability, today announced that the company will provide alerting technology to ... has been recently awarded $1.7 million in federal funds as the sole ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Fla. , Dec. 5, 2016  Breckenridge ... into a multi-product marketing agreement with development and ... injectable products. Under the terms of this agreement, ... its label in the United States ... and one tentatively-approved ANDA. The products cover a ...
(Date:12/5/2016)... , December 5, 2016 According to a new ... and by Application - Global Opportunity Analysis and Industry Forecast, 2014 - 2022", ... expected to reach $5,255 million by 2022, growing at a CAGR of 6.4% ... more than four-fifths share. Continue Reading ... ...
(Date:12/5/2016)... Sanovas, Inc., a life science asset holding company ... wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed Intubation ... http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed annually ...
Breaking Medicine Technology: